| Net loss | |
| Share-based compensation | 1.12M |
| Extinguishment of officer note receivable | |
| Change in fair value of contingent liability | |
| Issuance of common stock for intellectual property | |
| Charge for acquired in-process research and development | |
| Amortization of assembled workforce | |
| Amortization of debt discount and deferred interest | 2.25M |
| Amortization of premium (discount) on available-for-sale securities | |
| Depreciation and amortization | 3M |
| Write-off of other asset | |
| (Gain)/loss on disposal of property and equipment | 0 |
| Other receivables | 173K |
| Prepaid expenses and other current assets | -1.15M |
| Other assets | 1.81M |
| Accounts payable | -1.36M |
| Accrued clinical and other accrued liabilities | 558K |
| Deferred revenues | -2.67M |
| Other liabilities | -602K |
| Net cash provided by (used in) operating activities | |
| Purchases of available-for-sale securities | -5.8M |
| Maturities of available-for-sale securities | 25.29M |
| Purchases of available-for-sale securities held by Symphony Allegro, Inc. | |
| Maturities of available-for-sale securities held by Symphony Allegro, Inc. | |
| (Increase)/decrease in restricted cash | |
| Purchases of property and equipment | -58K |
| Proceeds from disposal of property and equipment | 15K |
| Cash paid for merger | |
| Net cash provided by (used in) investing activities | |
| Proceeds from issuance of common stock, common stock warrants and exercise of stock options and stock purchase rights, net of offering costs | |
| Repurchases of common stock | |
| Proceeds from issuance of convertible preferred stock | |
| Proceeds from repayment of stockholder note receivable | |
| Proceeds from purchase of noncontrolling interest in Symphony Allegro, Inc | |
| Proceeds from purchase of noncontrolling interest by preferred shareholders in Symphony Allegro, Inc, net of fees | |
| Payments of contingent payments to Symphony Allegro Holdings, LLC. | -868K |
| Proceeds from financing obligations | 2.91M |
| Payments of financing obligations | 0 |
| Net cash provided by financing activities | |
| Net increase (decrease) in cash and cash equivalents | -7.45M |
| Cash and cash equivalents at beginning of period | 15.2M |
| Cash and cash equivalents at end of period | 7.76M |